COMPARE · Data as of August 21, 2026
EXEL vs INVA
Verdict: Side-by-side breakdown using the Bull Rankings model. EXEL scored 74.1, INVA scored 68.6 — EXEL leads.
Compare another set
EXEL
Exelixis, Inc.
74.1
$54.08 · $13.4B
fundamentals as of
Score gap
5.5
EXEL leads
INVA
Innoviva, Inc.
68.6
$21.07 · $1.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestINVA4.9x
- Fastest growthINVA+18.8%
- Strongest balance sheetEXEL0.09
- Highest qualityEXEL97 / 100
- Largest discount to fair valueINVA-59%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
EXEL
stronger →← stronger
INVA
97
Qualityreturns · margins · balance sheet
69
80
Growthrevenue & earnings expansion
49
53
Valuevaluation vs sector peers
95
EXEL is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
EXEL
INVA
$1.2bC+
FCF
$189mC
+9.2%B
Rev
+18.8%B+
0.09B+
D/E
0.27B
17.0xA-
P/E
4.9xA
2.56C
PEG
0.31A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
EXEL
INVA
42% below
Price vs fair valuelower is cheaper
59% below
~-3%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-11%/yr
+45%
1-yr DCF upside
+106%
+72%
5-yr DCF upside
+142%
+118%
10-yr DCF upside
+205%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
EXEL
Why this score
- Buying back stock
- Durable high returns
INVA
Why this score
- Diluting shareholders
The companies
EXELExelixis, Inc.
Why now
Biotechnology · market cap $13.4b. 6% off the 52-week high of $57.57. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.00 (implying -2% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
INVAInnoviva, Inc.
Why now
Biotechnology · market cap $1.5b. 16% off the 52-week high of $25.15. Revenue growing +19%, comfortably above the S&P median. PEG 0.31 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Buy with a mean 1-yr target of $35.00 (implying +66% upside).
Moat
Net margin 81% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where EXEL and INVA diverge
On the headline score the gap is 5.5 points in favor of EXEL. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueEXEL 52.5 · INVA 95.2INVA +42.7
- GrowthEXEL 80.0 · INVA 49.2EXEL +30.8
- QualityEXEL 96.8 · INVA 69.0EXEL +27.8
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.